Edwards tweaks 2025 outlook amid strong Q2 heart therapy performance
Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% over the same period.
25 July 2025
Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% over the same period.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.